HUS-MPGN-TTP. & related disorders
|
|
|
- Karin Wheeler
- 5 years ago
- Views:
Transcription
1 ES-PCR 4 th International Conference HUS-MPGN-TTP & related disorders Current diagnosis and therapy of hemolytic uremic syndrome (HUS), membranoproliferative glomerulonephritis (MPGN), thrombotic thrombocytopenic purpura (TTP), and related disorders Hotel Grauer Bär Innsbruck,Austria June 9-11, 2013 Programme: Sunday, June Lectures and Free Communications Welcome reception Monday, June Lectures and Free Communications Postersession Wine & Cheese Transfer to Gala Dinner/ Tyrolean Night Tuesday, June Lectures and Free Communications Congress President: Reinhard.Wuerzner@i-med.ac.at,
2 Registration open: April 1 st May 31 th, 2013 Registration fee: EUR 250,00 Resident in training: EUR 150,00 Students: EUR 50,00 In the registration fee included are all meals, coffee breaks, welcome reception and Monday evening gala dinner. Hotel accommodation (please mention HUS-Meeting ) Hotel Grauer Bär, Universitätsstraße 5-7, 6020 Innsbruck grauer-baer@innsbruck-hotels.at Reduced rate for participants: Single 78 (including breakfast and all taxes) Double 120 (including breakfast and all taxes)
3 Sunday, June 9 10:00 18:30 Registration open 13:00 Welcome from Innsbruck Medical University Lochs/Würzner I. Introductory session Basics 13:15 L1 Complement & Diagnostics Kirschfink 14:00 L2 Inherited complement-related renal diseases: genetics Rodriguez de Cordoba 14:30 L3 Acquired complement-related renal diseases: antibodies Jozsi 15:00 L4 Secondary causes of complement-related renal diseases Fremeaux-Bacchi 15:30 16:00 Coffee break II. Introductory session Clinics 16:00 L5 Classification & Pathology of complement-related renal diseases Sethi 16:30 L6 Animal studies in complement-related renal diseases Pickering 17:00 L7 Treatment of complement-related renal diseases Licht 17:30 FC1 Screening of genes encoding complement (regulatory) proteins in patients with C3 glomerulopathy Westra 17:45 FC2 Recessive mutations in DGKE cause ahus Lemaire 18:00 Welcome reception
4 Monday, June 10 III: TTP 08:30 L8 Inherited TTP (Upshaw Schulman Syndrome) in childhood Schneppenheim 09:00 L9 Clinical presentation and differential diagnostics in TTP Coppo 09:30 L10 Treatment of TTP Knöbl 10:00 10:30 Coffee break IV: Clinical courses of complement-related renal diseases cases Chairs: Van de Kar & N.N. 10:30 C1 A 7 yr old boy with HUS and response to i.v. steroids Safouh 10:45 C2 An unusual case of thrombotic microangiopathy of unknown aetiology Sørensen 11:00 C3 Eculizumab and ahus: a complicated case with frequent replapses Schalk 11:15 C4 A successful use of Eculizumab in a case of ahus in pregnancy Ardissino 11:30 C5 Successful treatment of MPGN type II associated with autoantibodies against complement factor C3b with immunoadsorption Vinke 11:45-13:00 Lunch break
5 V. Typical HUS Outbreak I 13:00 L11 Epidemiology of O104:H4 Werber 13:30 L12 Molecular characteristics of O104:H4 Karch 14:00 L13 Clinical data adults Stahl 14:30 15:00 Coffee break VI. Typical HUS Outbreak II & Host responses 15:00 L14 Clinical data children Kemper 15:30 FC3 Human serum amyloid protects human podocytes from shiga toxin 2 induced activation of mitogen-activated protein kinases and apoptosis Dettmar 15:45 FC4 Shiga toxin 2 induces apoptosis and a proinflammatory phenotype in human glomerular endothelial cells Betzen 16:00 L15 Innate & inflammatory immune responses Palermo 16:30 18:30 Poster Session with wine and cheese 18:30 18:45 Transfer: 5 min. walk to the funicular 20:00 Tyrolean Night - Congress Dinner at the Seegrube, overlooking Innsbruck
6 Tuesday, June 11 VII. Typical HUS & complement - updates 08:30 L16 Downregulation of membrane inhibitor CD59 by shiga toxin 2 Orth-Höller and Würzner 08:55 L17 Endothelial injury & generation of complement-activating microparticles Thurman 09:20 L18 Blood cell derived microparticles in typical HUS Karpman 09:45 L19 Complement activation in STEC-HUS: from disease pathogenesis to therapy Noris 10:10 10:45 Coffee break VIII. Treatment with Eculizumab 10:45 L20 Eculizumab in PNH Röth 11:15 L21 Eculizumab in DDD & MPGN Vivarelli and Emma 11:45 FC5 Frontline treatment for ahus: plasma exchange or Eculizumab Paglialonga 12:00 FC6 Long-term Eculizumab treatment of patients with ahus with a long disease duration & chronic kidney disease: efficacy &safety Licht 12:15 FC7 ahus and progressing thrombotic microangiopathy (TMA): longterm improvements with Eculizumab Loirat 12:30 FC8 Discontinuation of Eculizumab maintenance treatment in patients with ahus Testa 12:45 FC9 Eculizumab drug monitoring in complement-mediated nephropathies Wehling and Kirschfink 13:00 14:00 Farewell and lunch
Atypical hemolytic uremic syndrome (ahus)
Sunday, July 12 10:00-18:30 Registration open I. Atypical hemolytic uremic syndrome (ahus) Chairs: Kronenberg, Speth 13:00 L1 ahus Role of complemet, overview Meri, FI 13:30 L2 ahus Role of lectin pathway
Recent advances in pathogenesis & treatment of ahus
Recent advances in pathogenesis & treatment of ahus Miquel Blasco Pelicano Nephrology and Kidney Transplant Unit Hospital Clínic, Barcelona Atypical Hemolytic Uremic Syndrome (ahus) Ultra-rare disease:
Beyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura
Beyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura Kristen Knoph, PharmD, BCPS PGY2 Pharmacotherapy Resident Pharmacy Grand Rounds April 25, 2017 2016 MFMER slide-1 Objectives
Medical Policy. MP Eculizumab (Soliris) Related Policies None. Last Review: 01/24/2019 Effective Date: 04/25/2019 Section: Prescription Drug
Medical Policy Last Review: 01/24/2019 Effective Date: 04/25/2019 Section: Prescription Drug Related Policies None DISCLAIMER Our medical policies are designed for informational purposes only and are not
What is meant by Thrombotic Microangiopathy (TMA)?
What is meant by Thrombotic Microangiopathy (TMA)? Thrombotic Microangiopathy (TMA) is a group of disorders characterized by injured endothelial cells, microangiopathic hemolytic anemia (MAHA), with its
Thrombotic Microangiopathies (TMA) / TTP/HUS/αHUS Pathology & Molecular. Genetics
Thrombotic Microangiopathies (TMA) / TTP/HUS/αHUS Pathology & Molecular Genetics Helen Liapis, M.D. Senior Consultant Arkana Labs Professor of Pathology & Immunology. retired Washington University School
DRUG NAME: Eculizumab Brand(s): Soliris DOSAGE FORM/ STRENGTH: 10 mg/ml (300 mg per vial)
Preamble: A confirmed diagnosis of atypical hemolytic uremic syndrome (ahus) is required for eculizumab funding. The information below is to provide clinicians with context for how a diagnosis of ahus
Hemolytic uremic syndrome
Hemolytic uremic syndrome Doyeun Oh Department of Internal Medicine CHA University School of Medicine Disclosures for Doyeun Oh Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau
Atypical Hemolytic Uremic Syndrome: When the Environment and Mutations Affect Organ Systems. A Case Report with Review of Literature
Atypical Hemolytic Uremic Syndrome: When the Environment and Mutations Affect Organ Systems. A Case Report with Review of Literature Mouhanna Abu Ghanimeh 1, Omar Abughanimeh 1, Ayman Qasrawi 1, Abdulraheem
MUSCULOSKELETAL SONOGRAPHY COURSE FOR RHEUMATOLOGISTS - BASIC LEVEL - June 27 th 29 th, 2013 Innsbruck, Austria
MUSCULOSKELETAL SONOGRAPHY COURSE FOR RHEUMATOLOGISTS - BASIC LEVEL - June 27 th 29 th, 2013 Innsbruck, Austria GENERAL INFORMATION Course opening: Thursday, June 27 th, 2013 - h 12.00 Course closing:
September 14 th 16 th, 2017 Innsbruck, Austria
MUSCULOSKELETAL SONOGRAPHY COURSE FOR RHEUMATOLOGISTS - BASIC LEVEL - September 14 th 16 th, 2017 Innsbruck, Austria This course is scientifically endorsed by: GENERAL INFORMATION Course opening: Thursday,
THROMBOTIC MICROANGIOPATHY. Jun-Ki Park 7/19/11
THROMBOTIC MICROANGIOPATHY Jun-Ki Park 7/19/11 TMAs are microvascular occlusive disorders characterized by systemic or intrarenal aggregation of platelets, thrombocytopenia, and mechanical injury to erythrocytes.
Risk factors of chronic renal failure after atypical Hemolytic Uremic Syndrome under plasmatherapy
Risk factors of chronic renal failure after atypical Hemolytic Uremic Syndrome under plasmatherapy Professeur Eric Rondeau Urgences néphrologiques et Transplantation rénale Hôpital Tenon, Paris WWA SFH
From MPGN to C3G. F Fakhouri, Nantes, France. «Membranoproliferative» is a pathological feature. Mesangial expansion «Doubles contours»
From MPGN to C3G F Fakhouri, Nantes, France Conflits d intérêt: consultant auprès d Alexion Pharmaceuticals «Membranoproliferative» is a pathological feature Mesangial expansion «Doubles contours» Immune
Hemolytic Uremic Syndrome
Hemolytic Uremic Syndrome Francesco Emma Division of Nephrology and Dialysis Bambino Gesù Children s Hospital, IRCCS Rome, Italy Hemolytic Uremic Syndrome (HUS) microangiopathic hemolytic anemia thrombocytopenia
June 26 th 28 th, 2014 Innsbruck, Austria
MUSCULOSKELETAL SONOGRAPHY COURSE FOR RHEUMATOLOGISTS - INTERMEDIATE LEVEL - June 26 th 28 th, 2014 Innsbruck, Austria This course is scientifically endorsed by: GENERAL INFORMATION Course opening: Thursday,
M.Weitz has documented that he has no relevant financial relationships to disclose or conflict of interest to resolve.
M.Weitz has documented that he has no relevant financial relationships to disclose or conflict of interest to resolve. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic
Soliris and You. Your Guide To Living With ahus. INDICATION & IMPORTANT SAFETY INFORMATION FOR SOLIRIS (eculizumab)
INDICATION & IMPORTANT SAFETY INFORMATION FOR SOLIRIS (eculizumab) INDICATION What is SOLIRIS? SOLIRIS is a prescription medicine called a monoclonal antibody. SOLIRIS is used to treat: adults and children
September 5 th 7 th, 2018 Innsbruck, Austria
MUSCULOSKELETAL SONOGRAPHY COURSE FOR RHEUMATOLOGISTS - INTERMEDIATE LEVEL - September 5 th 7 th, 2018 Innsbruck, Austria This course is scientifically endorsed by: GENERAL INFORMATION Course opening:
New insights in thrombotic microangiopathies : TTP and ahus
New insights in thrombotic microangiopathies : TTP and ahus Dr Catherine LAMBERT Hematology Cliniques universitaires Saint-Luc Catherine.lambert@uclouvain.be New insights in thrombotic microangiopathies
Safety and Efficacy of Eculizumab in Pediatric Patients With ahus, With or Without Baseline Dialysis
SA-PO546 Safety and Efficacy of Eculizumab in Pediatric Patients With ahus, With or Without Baseline Johan Vande Walle, 1 Larry A. Greenbaum, 2 Camille L. Bedrosian, 3 Masayo Ogawa, 3 John F. Kincaid,
ahus A PATIENT S GUIDE To learn more about ahus, visit Copyright 2011, Alexion Pharmaceuticals, Inc. All rights reserved.
To learn more about ahus, visit www.ahussource.com ahus A PATIENT S GUIDE Copyright 2011, Alexion Pharmaceuticals, Inc. All rights reserved. SOL 1169 BECOME EMPOWERED By learning more and taking control
Soliris (eculizumab) DRUG.00050
Market DC Soliris (eculizumab) DRUG.00050 Override(s) Prior Authorization Approval Duration 1 year Medications Soliris (eculizumab) APPROVAL CRITERIA Paroxysmal Nocturnal Hemoglobinuria I. Initiation of
Soliris. Soliris (eculizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.11 Subject: Soliris Page: 1 of 5 Last Review Date: September 20, 2018 Soliris Description Soliris
TMA in HUS and TTP: new insights
TMA in HUS and TTP: new insights Daan Dierickx University Hospitals Leuven, Department of Hematology, Belgium 20th Annual Meeting Belgian Society on Thrombosis and Haemostatis Antwerpen, 22 th November
Hemolytic uremic syndrome: Investigations and management
Hemolytic uremic syndrome: Investigations and management SAWAI Toshihiro M.D., Ph.D. Department of Pediatrics, Shiga University of Medical Science Otsu, JAPAN AGENDA TMA; Thrombotic micro angiopathy STEC-HUS;
Clinical Study Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome
Hindawi Publishing Corporation Advances in Hematology Volume 214, Article ID 295323, 7 pages http://dx.doi.org/1.1155/214/295323 Clinical Study Therapy Leads to Rapid Resolution of Thrombocytopenia in
Atypical hemolytic uremic syndrome. Diana Karpman Department of Pediatrics Lund University
Atypical hemolytic uremic syndrome Diana Karpman Department of Pediatrics Lund University Image courtesy of Dr. Sabine Leh, Haukeland University Hospital, Bergen Norway Hemolytic Uremic Syndrome Non-immune
R. Coward has documented that he has received cooperative grants from Takeda and Novo Nordisk
R. Coward has documented that he has received cooperative grants from Takeda and Novo Nordisk Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy Lindsay Keir Richard
THE MULTIPLE FACETS OF THROMBOTIC MICROANGIOPATHIES
THE MULTIPLE FACETS OF THROMBOTIC MICROANGIOPATHIES Summary of Presentations from the Alexion-Sponsored Symposium, held at the 19 th EHA Congress, Milan, Italy, on 12 th June 2014 Chairperson Pier Mannuccio
Corporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: eculizumab_soliris 8/2014 4/2018 4/2019 4/2018 Description of Procedure or Service Paroxysmal nocturnal hemoglobinuria
Spectrum of complement-mediated thrombotic microangiopathies after kidney transplantation
Spectrum of complement-mediated thrombotic microangiopathies after kidney transplantation Marius Miglinas Vilnius university hospital: Nephrology center, Center of Rare Kidney Diseases Vilnius university
Review Article Kidney Diseases Caused by Complement Dysregulation: Acquired, Inherited, and Still More to Come
Clinical and Developmental Immunology Volume 2012, Article ID 695131, 6 pages doi:10.1155/2012/695131 Review Article Kidney Diseases Caused by Complement Dysregulation: Acquired, Inherited, and Still More
PROVISIONAL SCIENTIFIC PROGRAMME AND TIMETABLE
PROVISIONAL SCIENTIFIC PROGRAMME AND TIMETABLE Thursday 17 th October, 2013 09.00- : Executive meetings (only for the Executive and the International Advisory Boards of EURIPA and the Executive of EGPRN),
Introduction to pathogenesis and treatment of thrombotic microangiopathies (TMA)
Introduction to pathogenesis and treatment of thrombotic microangiopathies (TMA) JM.Campistol, Nephrology and Renal Transplant Department, Hospital Clinic, University of Barcelona, Barcelona, Spain. jmcampis@clinic.cat
Challenges in Renal Apheresis. Mark E. Williams MD, FACP, FASN Director, Renal Apheresis Beth Israel Deaconess Medical Center Harvard Medical School
Challenges in Renal Apheresis Mark E. Williams MD, FACP, FASN Director, Renal Apheresis Beth Israel Deaconess Medical Center Harvard Medical School Outline Principles of Separation ASFA Guidelines Renal
Accepted Manuscript. No more thrombotic thrombocytopenic purpura/hemolytic uremic syndrome please. Yeong-Hau H. Lien MD, PhD S (18)
Accepted Manuscript No more thrombotic thrombocytopenic purpura/hemolytic uremic syndrome please Yeong-Hau H. Lien MD, PhD PII: S0002-9343(18)30965-3 DOI: https://doi.org/10.1016/j.amjmed.2018.10.009 Reference:
Soliris (eculizumab) Inhibits TMA and Improves Renal Function in Pediatric and Adult Patients with atypical Hemolytic Uremic Syndrome (ahus)
Soliris (eculizumab) Inhibits TMA and Improves Renal Function in Pediatric and Adult Patients with atypical Hemolytic Uremic Syndrome (ahus) New Data from the Largest Prospective Trial of Adult Patients
When a patient presents with TMA, identify the underlying cause for the appropriate diagnosis... IS IT TTP OR IS IT ahus?
When a patient presents with TMA, identify the underlying cause for the appropriate diagnosis... IS IT TTP OR IS IT ahus? ADAMTS13 activity >5% RULES OUT a diagnosis of severe ADAMTS13 deficiency (TTP)
Medication Prior Authorization Form
Policy Number: 1054 Policy History Approve Date: 06/01/2018 Effective Date: 06/01/2018 Preauthorization All Plans Benefit plans vary in coverage and some plans may not provide coverage for certain service(s)
Coding... 5 Benefit Application... 5 Description of Services... 6 Clinical Evidence... 7
TABLE OF CONTENTS Product Variations.... 1 Policy Statement.... 1 Related Policies.... 4 Policy Guidelines..... 4 Coding.... 5 Benefit Application........ 5 Description of Services..... 6 Clinical Evidence.......
PNH ahus. Dosing and Administration. For Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (ahus) patients
For Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (ahus) patients PNH ahus Dosing and Administration Soliris is indicated for the treatment of patients with paroxysmal
DIAGNOSTIC CHALLENGES IN THROMBOTIC MICROANGIOPATHIES
DIAGNOSTIC CHALLENGES IN THROMBOTIC MICROANGIOPATHIES Summary of Presentations from the Alexion-Sponsored Symposium, held at the 51 st ERA EDTA Congress, Amsterdam, the Netherlands, on 1 st June 2014 Chairperson
HUS and TTP Testing. Kenneth D. Friedman, M.D. Director, Hemostasis Reference Lab BloodCenter of Wisconsin, Milwaukee WI
HUS and TTP Testing Kenneth D. Friedman, M.D. Director, Hemostasis Reference Lab BloodCenter of Wisconsin, Milwaukee WI Disclosures Relevant Financial Relationships Consultant: Ablynx, Bayer, CSL Behring,
C3 Glomerulopathy. Jun-Ki Park
C3 Glomerulopathy Jun-Ki Park 03.08.11 For the last 30 years classification MPGN is based on glomerular findings by light microscopy with further specification on EM and staining for Ig and complement
A 23 year old Caucasian male presented with shortness of breath, hypertension, bloody sputum, and a history of drug abuse (confirmed by urinalysis).
A 23 year old Caucasian male presented with shortness of breath, hypertension, bloody sputum, and a history of drug abuse (confirmed by urinalysis). He was found to have severe kidney injury requiring
Can eculizumab be discontinued in ahus? Case report and review of the literature
Clinical Case Report Medicine Can eculizumab be discontinued in ahus? Case report and review of the literature Tuncay Sahutoglu, MD a,, Taner Basturk, MD a, Tamer Sakaci, MD a, Yener Koc, MD a, Elbis Ahbap,
An international consensus approach to the management of atypical hemolytic uremic syndrome in children
DOI 10.1007/s00467-015-3076-8 REVIEW An international consensus approach to the management of atypical hemolytic uremic syndrome in children Chantal Loirat & Fadi Fakhouri & Gema Ariceta & Nesrin Besbas
Index. electron microscopy, 81 immunofluorescence microscopy, 80 light microscopy, 80 Amyloidosis clinical setting, 185 etiology/pathogenesis,
A Acute antibody-mediated rejection (Acute AMR) clinical features, 203 clinicopathologic correlations, 206 pathogenesis, 205 206 204 205 light microscopy, 203 204 Acute cellular rejection (ACR) clinical
PNH ahus gmg. Dosing and Administration Guide
Injection for Intravenous Use PNH ahus gmg For Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (ahus), and generalized Myasthenia Gravis (gmg) patients Dosing and Administration
LABORATORY ANIMAL SCIENCE ASSOCIATION. Information Booklet
LABORATORY ANIMAL SCIENCE ASSOCIATION Information Booklet Platinum Sponsor: Gold Sponsors: Silver Sponsors: Bronze Sponsors: Welcome! We are pleased to invite you to Birmingham for the 2017 LASA Annual
COMPLEMENT INHIBITORS (SOLIRIS & ULTOMIRIS )
COMPLEMENT INHIBITORS (SOLIRIS & ULTOMIRIS ) Protocol: PHA029 Effective Date: March 1, 2019 Table of Contents Page COVERAGE RATIONALE... 1 US FOOD AND DRUG ADMINISTRATION (FDA)... 4 BACKGROUND... 4 APPLICABLE
Applied Clinical Nephrology Course
Applied Clinical Nephrology Course 24 th &25 th October 2015 Venue: Doubletree by Hilton Hotel, Manchester, UK Introduction The aim of this course is to provide an interactive comprehensive up to date
Thrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome
Sallée et al. BMC Nephrology 2013, 14:3 RESEARCH ARTICLE Open Access Thrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome Marion Sallée 1, Khalil Ismail 1, Fadi Fakhouri 2, Henri
C3 Glomerulonephritis versus C3 Glomerulopathies?
Washington University School of Medicine Digital Commons@Becker Kidneycentric Kidneycentric 2016 C3 Glomerulonephritis versus C3 Glomerulopathies? T. Keefe Davis Washington University School of Medicine
Access to ahus Treatment: 2016 ahus Global Poll White Paper
Access to ahus Treatment: 2016 ahus Global Poll White Paper Orphan Drug Access Are Rare Disease Treatments like Eculizumab Equally Available Worldwide? In an era of social media, sharing patient stories
Thrombotic Microangiopathy (TMA) The Clinical Facets of TMA
International Consensus on Management Atypical Hemolytic Uremic Syndrome in Children Loirat C. et al. Pediatr Nephrol 31: 15-39, 2016 Ruth A. McDonald, MD Professor and Vice Chair Clinical Affairs Department
Specialised Services Policy: CP98 Eculizumab for Atypical Haemolytic Uraemic Syndrome (ahus)
Specialised Services Policy: CP98 Eculizumab for Atypical Haemolytic Uraemic Syndrome (ahus) Document Author: Assistant Director for Evidence, Evaluation and Effectiveness Executive Lead: Medical Director
Thrombotic microangiopathy and indications for therapeutic plasma exchange
SPIN DOCTORS:APHERESIS FOR HEMATOLOGISTS Thrombotic microangiopathy and indications for therapeutic plasma exchange Jill Adamski 1 1 Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona,
Safety and Efficacy of Eculizumab in Pediatric Patients With ahus, With or Without Baseline Dialysis
SP281 Safety and Efficacy of Eculizumab in Pediatric Patients With ahus, With or Without Baseline Johan Vande Walle, 1 Larry A. Greenbaum, 2 Camille L. Bedrosian, 3 Masayo Ogawa, 3 John F. Kincaid, 3 Chantal
Pathology of Complement Mediated Renal Disease
Pathology of Complement Mediated Renal Disease Mariam Priya Alexander, MD Associate Professor of Pathology GN Symposium Hong Kong Society of Nephrology July 8 th, 2017 2017 MFMER slide-1 The complement
SINGAPORE. 12 th PVRI Annual World Congress. on Pulmonary Vascular Disease WELCOME TO. Date // January 2018
Date // 21-25 January 2018 12 th PVRI Annual World Congress on Disease Hotel // Mandarin Orchard Hotel. Singapore WELCOME TO SINGAPORE Pre-Congress MEETINGS Sunday 21 January 2018 PVRI Board of Directors
Haemolytic uraemic syndrome the story of a whodunit
Haemolytic uraemic syndrome the story of a whodunit Paul Warwicker Lancashire Teaching Hospitals NHS Trust RCP Kidney for the General Physician Conference Nov 17 Renal thrombotic microangiopathy (TMA)
Initial management of TMA syndromes
Initial management of TMA syndromes Elie Azoulay, Saint-Louis Hospital, Medical Intensive Care Unit Paris Diderot Sorbonne University Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique
Saturday 8/26/2017 7:00am - 7:00pm Closed 11:00am - 9:00pm Closed Closed
Fall 2017 Opening Weekend Friday 8/25/2017 7:00am - 7:00pm Closed 8:30am - 2:00pm Closed Closed Saturday 8/26/2017 7:00am - 7:00pm Closed 11:00am - 9:00pm Closed Closed Sunday 8/27/2017 7:30 am - 2:00
RaDaR Newsletter. Issue Four, Winter 2016
RaDaR Newsletter Issue Four, Winter 2016 The National Registry of Rare Kidney Diseases (RaDaR) is a Renal Association initiative designed to pull together information from patients with certain rare kidney
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Soliris (eculizumab) Page 1 of 11 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Soliris (eculizumab) Prime Therapeutics will review Prior Authorization requests
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Lapeyraque A-L, Malina M, Fremeaux-Bacchi V, et al. Eculizumab
Joint Banff/CST Program Committee Co-chairs: Dr. Alexandre Loupy and Dr. Prosanto Chaudhury. Joint Banff/CST Finance Committee
2015 Banff/CST Meeting Organizing Corporation ( 2015 MOC ) Co-Directors: Dr. John Gill, Dr. Michael Mengel Members: Anthony Jevnikar, David Rush, Denis Glotz, Kim Solez, Marcelo Cantarovich, Mark Haas,
LABORATORY ANIMAL SCIENCE ASSOCIATION. Annual Conference Information Booklet
LABORATORY ANIMAL SCIENCE ASSOCIATION Information Booklet Platinum Sponsors: Gold Sponsor: Silver Sponsors: Bonze Sponsors: Welcome! We would like to thank LASA s team of Meeting Section Conveners for
Thrombotic Microangiopathy and the Kidney
CJASN epress. Published on October 17, 2017 as doi: 10.2215/CJN.00620117 Thrombotic Microangiopathy and the Kidney Vicky Brocklebank,* Katrina M. Wood, and David Kavanagh* Abstract Thrombotic microangiopathy
Sacha Zeerleder, MD PhD Internist-hematologist Academic Medical Centre, Amsterdam Sanquin Research, Amsterdam
Sacha Zeerleder, MD PhD Internist-hematologist Academic Medical Centre, Amsterdam Sanquin Research, Amsterdam Sacha Zeerleder, MD PhD Internist-hematologist Academic Medical Centre, Amsterdam Sanquin Research,
Pathogenetic mechanisms in atypical HUS
Pathogenetic mechanisms in atypical HUS Seppo Meri University & University Hospital Helsinki, Finland Antalya, Turkey Photo: Markku Kallio 21.10.2017 HUS after eating Kebab - 22 yo female - watery diarrhea
Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab
Nephrol Dial Transplant (2014) 29: iv131 iv141 doi: 10.1093/ndt/gfu235 Full Review Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab Jacobien C. Verhave 1, Jack F.M. Wetzels
Welcome to the Inner Ear Biology 2016
SPONSORSHIP FILE More than 400 Biologists, Physician (disciplines of Audiology and Phoniatrics, Otolaryngology, Neurology and Pediatric Neuropsychiatrist); Audiometrists, Hearing Aid Dispensers, Audiologists
Hemolytic uremic syndrome with simultaneous Shiga toxin producing Escherichia coli and complement abnormalities
McCoy and Weaver BMC Pediatrics 2014, 14:278 CASE REPORT Open Access Hemolytic uremic syndrome with simultaneous Shiga toxin producing Escherichia coli and complement abnormalities Nicole McCoy 1 and Donald
C3G An Update What is C3 Glomerulopathy Anyway? Patrick D. Walker, M.D. Nephropath Little Rock, Arkansas USA
C3G An Update What is C3 Glomerulopathy Anyway? Patrick D. Walker, M.D. Nephropath Little Rock, Arkansas USA C3 Glomerulopathy Overview Discuss C3 Glomerulopathy (C3G) How did we get to the current classification
The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry
research paper The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry Sevda Hassan, 1 John-Paul Westwood, 2 Debra Ellis, 2 Chris
Guideline. Abstract. Key words
bs_bs_banner Pediatrics International (2014) 56, 1 5 doi: 10.1111/ped.12274 Guideline Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society
A 60 year old woman with altered mental status and thrombotic microangiopathy. Josh Veatch
A 60 year old woman with altered mental status and thrombotic microangiopathy Josh Veatch Previously healthy 60 year old woman 2 3 months of fatigue following a URI, transient episodes being out of it
Two Patients With History of STEC-HUS, Posttransplant Recurrence and Complement Gene Mutations
American Journal of Transplantation 2013; 13: 2201 2206 Wiley Periodicals Inc. Case Report C Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons doi:
Core Curriculum in Nephrology
Core Curriculum in Nephrology Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core
Thrombotic Thrombocytopenic Purpura and the Role of ADAMTS-13
Thrombotic Thrombocytopenic Purpura and the Role of ADAMTS-13 Mark Cunningham,MD Director, Hematology Laboratory Department of Pathology University of Kansas Medical Center College of American Pathologists
DIOXIN SYMPOSIUM MEETING PLANNING
DIOXIN SYMPOSIUM MEETING PLANNING History & General Information A listing of future and past Dioxin Symposia can be found on the Symposium page. The International Dioxin Symposium has been held annually
14 TH EULAR POSTGRADUATE COURSE
14 TH EULAR POSTGRADUATE COURSE 18 21 November 2013 Prague, Czech Republic ORGANISATION AND COMMITTEE Scientific organiser Professor Ingrid Lundberg, Stockholm, Sweden Chairperson elect EULAR standing
16 TH EULAR POSTGRADUATE COURSE
16 TH EULAR POSTGRADUATE COURSE 18 21 October 2015 Prague, Czech Republic ORGANISATION AND COMMITTEE Scientific organiser Professor Annamaria Iagnocco, Italy Chairperson EULAR standing Committee on Education
W J N. World Journal of Nephrology. Complement involvement in kidney diseases: From physiopathology to therapeutical targeting.
W J N World Journal of Nephrology Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5527/wjn.v4.i2.169 World J Nephrol 2015 May 6; 4(2): 169-184
Microangiopatia trombotica (MAT) e Sindrome emolitico-uremica atipica (SEUa): Basi patogenetiche, inquadramento diagnostico e principi del
Microangiopatia trombotica (MAT) e Sindrome emolitico-uremica atipica (SEUa): Basi patogenetiche, inquadramento diagnostico e principi del trattamento Vincenzo Montinaro U.O. Nefrologia Azienda Ospedaliera
Soliris Medical Policy Prior Authorization Program Summary
Soliris Medical Policy Prior Authorization Program Summary Precertification/Prior Authorization may be required under certain plans. Please verify each member s benefits. OBJECTIVE The intent of the Soliris
Organized in Partnership with the Thai Society of Hematology (TSH)
Organized in Partnership with the Thai Society of Hematology (TSH) You're invited to the ISTH Workshop on Thrombosis and Hemostasis in Bangkok, Thailand. This workshop is designed to offer the latest training
Fall 2018: Spring 2019:
Fall 2018: Fall 2018 Opening Weekend Fall Break 2018 Thanksgiving Break 2018 Finals Week Fall 2018 Winter Break 2018 Spring 2019: Spring 2019 Opening Weekend Spring Break 2019 Easter Break 2019 Finals
EUROPEAN RADIATION RESEARCH SOCIETY
40th Annual Meeting of the EUROPEAN RADIATION RESEARCH SOCIETY 1-5 SEPT. 2013 DUBLIN CASTLE IRELAND WWW.ERR2013.IE Welcome Note On behalf of the Irish Radiation Research Society and the Association for
H. Terence Cook. REVIEW C3 glomerulopathy [version 1; referees: 4 approved] Open Peer Review. Referee Status:
![H. Terence Cook. REVIEW C3 glomerulopathy [version 1; referees: 4 approved] Open Peer Review. Referee Status:](/thumbs/94/119185743.jpg "H. Terence Cook. REVIEW C3 glomerulopathy [version 1; referees: 4 approved] Open Peer Review. Referee Status:")
REVIEW C3 glomerulopathy [version 1; referees: 4 approved] H. Terence Cook Department of Medicine, Imperial College London, Hammersmith, London, UK v1 First published: 10 Mar 2017, 6(F1000 Faculty Rev):248
Introduction. Arif Asif 1 Ali Nayer 2 Christian S. Haas 3
J Nephrol (2017) 30:347 362 DOI 10.1007/s40620-016-0357-7 REVIEW Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment
w ahus pathology is linked to dysregulation of the alternative complement pathway.
ahus - Pathogenesis, Etiology, and Clinical Advances Craig B. Langman MD The Isaac A Abt MD Professor of Kidney Diseases Feinberg School of Medicine, Northwestern University Head, Kidney Diseases The Ann
A PATIENT S JOURNEY. Learning about atypical hemolytic uremic syndrome (ahus)
A PATIENT S JOURNEY Learning about atypical hemolytic uremic syndrome (ahus) Begin your path to empowerment Being diagnosed with ahus can be overwhelming. You may have many questions: What is ahus? How
A Case of Escherichia coli Hemolytic Uremic Syndrome in a 10-Year-Old Male With Severe Neurologic Involvement Successfully Treated With Eculizumab
741144HICXXX10.1177/2324709617741144Journal of Investigative Medicine High Impact Case ReportsRasa et al research-article20172017 Case Report A Case of Escherichia coli Hemolytic Uremic Syndrome in a 10-Year-Old
Cigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Eculizumab Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 5 References... 6 Effective Date... 8/15/2018 Next
Les microangiopathies thrombotiques Quoi de neuf?
Les microangiopathies thrombotiques Quoi de neuf? Société des Sciences Vasculaires du Québec 16 Septembre 2016 Anne-Laure Lapeyraque CHU Sainte Justine, Montréal anne.laure.lapeyraque@umontreal.ca Objectifs